EGFR and non-small cell lung carcinoma: Standard-of-care for advanced NSCLC with sensitizing EGFR variants (e.g., exon 19 deletions, p.L8585R) are EGFR tyrosine kinase inhibitors (TKI) of the first (e.g., erlotinib, gefitinib), second (e.g., afatinib) and third generation (e.g., osimertinib) [5].